ArticleCureus2025
A Case of Avelumab-Resistant Upper Urothelial Carcinoma Responding to Pembrolizumab.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Complete Response to Pembrolizumab After Progression on Avelumab Maintenance in Metastatic Urothelial Carcinoma.IJU case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In patients previously treated with immune checkpoint inhibitors (ICIs) for malignancies, the efficacy and safety of re-challenging with the same or another type of ICI remain unclear. We experienced a case in which a patient responded to pembrolizumab as a salvage treatment despite primary resistance to avelumab as a maintenance treatment for metastatic upper urinary tract urothelial carcinoma (mUTUC). A 69-year-old female presented with anemia and microscopic hematuria, diagnosed as mUTUC with lymph node metastases. After receiving avelumab maintenance therapy following platinum-based chemotherapy, there was no response at all. The previous chemotherapy was re-administered, but unfortunately, bone metastases were newly detected. We subsequently administered pembrolizumab to the patient, resulting in reductions in both the primary and metastatic tumors. Even if the patient has primary resistance to the anti-programmed death-ligand 1 (PD-L1) antibody avelumab, the anti-programmed cell death 1 (PD-1) antibody pembrolizumab, as an ICI rechallenge, could be a treatment option for a limited number of patients with metastatic urothelial carcinoma (mUC).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.